Liao Guoyang

Dr. Liao Guoyang

Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
BHBo Hou
Bo Hou
LGLiao Guoyang
Liao Guoyang
XYXiao-Bei Yang
Xiao-Bei Yang
WZWen-Fei Zhu
Wen-Fei Zhu
JLJin-Yu Li
Jin-Yu Li
JZJun Zhou
Jun Zhou

10 May 2018 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
ZLZhuofan Li
Zhuofan Li
WDWenting Ding
Wenting Ding
QGQi Guo
Qi Guo
LGLiao Guoyang
Liao Guoyang
ZZZhe Zhu
Zhe Zhu
GLGuoyang Liao
Guoyang Liao
Sabin-based inactivated poliovirus vaccine(sIPV) is gradually replacing live-attenuated oral polio vaccine(OPV). Sabin-inactivated poliovirus vaccine(sIPV) has played a vital role in reducing economic burden of poliomyelitis and maintaining appropriate antibody levels in the population. However, due to its high cost and limited manufacturing capacity, sIPV cannot reach its full potential for global poliovirus eradication in developing countries. Therefore, to address this situation, we designed this study to evaluate the dose-sparing effects of AS03, CpG oligodeoxynucleotides (CpG-ODN) and polyinosinic:polycytidylic acid (PolyI:C) admixed with sIPV in rats. Our results showed that a combination of 1/4-dose sIPV adjuvanted with AS03 or AS03 with BW006 provides a seroconversion rate similar to that of full-dose sIPV without adjuvant and that, this rate is 5-fold higher than that of 1/4-dose sIPV without adjuvant after the first immunization. The combination of AS03 or AS03 with BW006 as an adjuvant effectively reduced sIPV dose by at least 4-fold and induced both humoral and cellular immune responses. Therefore, our study revealed that the combination of AS03 or AS03 with BW006 is a promising adjuvant for sIPV development.

7 December 2016 in Cellular Physiology and Biochemistry
Verified
Journal Article
Open access
PDF file
QGQi Guo
Qi Guo
LGLiao Guoyang
Liao Guoyang
JGJingxia Gao
Jingxia Gao
JZJian Zhou
Jian Zhou
WHWenzhu Hu
Wenzhu Hu
GLGuoyang Liao
Guoyang Liao
Background: There are sporadic cases and local outbreaks of H5N1 avian influenza virus worldwide every year. The World Health Organization (WHO) has paid close attention to the avian influenza epidemic trend. Avian influenza vaccines (AIV) are considered to be useful when an epidemic occurs. However, the use of AIV for humans is not yet widespread. Methods: This study assessed the immunogenicity and safety of pandemic influenza H5N1 vaccines with inactivated whole virus, split virus and subunit virus vaccines for healthy adults. We searched the databases of the Cochrane Central Register of Controlled Trials (CENTRAL), Medline, Excerpata Medica Database (EMBASE) and China National Knowledge Infrastructure (CNKI). The data from randomized trials regarding the immunogenicity and safety of AIV with or without different types of adjuvants for healthy adults (with an age range from 18 to 60 years) were collected. Results: According to this study, the most effective doses of H5N1 AIV ranged from 3.75 µg to 7.5 µg Hemagglutinin (HA) antigen. Aluminium adjuvants were administered with the same vaccine dose as a no-adjuvant group and induced the same immune effects. However, novel adjuvants (MF59 and AS03) were used with a smaller dose of vaccine than the no-adjuvant groups and successfully stimulated the body to produce more effective antibodies. Conclusion: All of the H5N1 AIV surveyed in this study were well tolerated without serious adverse reactions.

9 September 2020 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
LGLiao Guoyang
Liao Guoyang
XGXingliang Geng
Xingliang Geng
ZCZhaohai Cui
Zhaohai Cui
WLWeidong Li
Weidong Li
XOxia ou
xia ou
GLGuoyang Liao
Guoyang Liao
We generated plasmid pools for the rapid preparation of candidate vaccine strains, which could grow in the Vero cells at low temperature. Firstly, we cloned in the pHW2000 plasmid each of the eight gene segments (PB2, PB1, PA, hemagglutinin [HA], neuraminidase [NA], NS, NP, M) of two master donor strains (MDS), respectively, A/Yunnan/1/2005Vca(H3N2) and B/Yunnan/2/2005Vca(By), which had Vca phenotype (cold‐adapted phenotype in Vero cells). Secondly, the similar operation was implemented with each of the HA, NA and NP segments of circulating strains with epidemic potential (parental strains). The virus rescue techniques were employed in this study, according to the homology rate of HA segments between MDS and parental strains. Then, we harvested amount of new Vca virus strains. By transmission electron microscope, it could observe new viruses' diameter and length were from 100 to 120 nm. Importantly, these reassortant viruses could get high‐yield production in Vero cells at 25℃ from the beginning to the fourth generation, which was significantly differ from their original parental viruses. Additional, these production 16 new Vca strains could maintain enough antibody binding capacity and attenuation phenotype, which consisted with their MDS. So these plasmid pools constructed by mount of different influenza A and B virus gene fragments could present desired working performance and provide convenience and realization for more Vca reassortant virus as candidate vaccine strain if needing.

9 October 2018 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
SSShaohui Song
Shaohui Song
LGLiao Guoyang
Liao Guoyang
JZJian Zhou
Jian Zhou
WCWei Cai
Wei Cai
HYHuijuan Yang
Huijuan Yang
GLGuoyang Liao
Guoyang Liao

6 July 2017 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
YLYunfeng Long
Yunfeng Long
LMLei Ma
Lei Ma
ZLZe Liu
Ze Liu
SSShaohui Song
Shaohui Song
XGXingliang Geng
Xingliang Geng
LGLiao Guoyang
Liao Guoyang
Live attenuated influenza vaccine (LAIV)-based Vero cells could provide a better choice to control and prevent influenza virus infections. This study used the human influenza virus A/Yunnan/1/2005Vca(H3N2) (YN/05Vca) as a donor strain. YN/05Vca has a double phenotype of cold adaption (ca) and Vero cell adaption (va). The parental virus strain used was the wild-type A/Solomon Islands/3/2006 (H1N1) (SI/06wt). The study employed the modified classical reassortment method to generate a new virus strain. After co-infection of Vero cells, some different sub-types of the reassorted viruses were generated randomly. Then, the specific anti-serum (anti-YN/05Vca) could combine with and neutralize the donor virus, and the original parental virus could not grow in Vero cells at a low temperature until it was re-structured with the meaningful gene fragment from the donor virus in Vero cells. According to the plaques and RT-PCR results, a new monoclonal strain of Vero cell cold adaption virus was screened: SI/06Vca. After immunological and biological identification, this new strain virus could be used as a seed bank for LAIV, which has maintained surface antigenicity with SI/06wt. Consequently, this new Vero cell cold adaption virus SI/06Vca could be used for large-scale vaccine production with sufficient safety and efficacy, as confirmed by animal experiments with mice and ferrets.